| Are we ready to ring in a new upfront therapy in lower-risk myelodysplastic syndromes? |
|
Lancet |
Myelodysplastic Syndromes (MDS) |
| Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
| Author Correction: Fit older adults with advanced myelodysplastic syndromes: who is most likely to benefit from transplant? |
|
Leukemia |
Myelodysplastic Syndromes (MDS) |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Baseline Clinical Characteristics and Disease Burden in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH): Updated Analysis From the International PNH Registry |
|
Annals of Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Beneficial effects of eculizumab regardless of prior transfusions or bone marrow disease: Results of the International PNH Registry |
|
European Journal of Haematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Calculator-free point-of-care prognostication in myelodysplastic syndromes. |
|
Am J Hematol |
Myelodysplastic Syndromes (MDS) |
| Cardiac and genetic predictors of cardiovascular risk in patients with myelodysplastic syndromes |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
